Anti-Mouse CD200 (Clone OX-90) – Purified in vivo GOLD™ Functional Grade

Clone OX-90 is commonly used in vivo in mice for studies that require blockade or detection of CD200 (OX-2), a cell-surface glycoprotein primarily involved in modulating immune responses.

Key in vivo applications include:

• Blocking CD200–CD200R interaction: OX-90 is widely used to block the immunosuppressive CD200–CD200R signaling pathway in vivo, thereby unleashing or augmenting immune activity. Blocking this interaction can increase myeloid cell activity and lower their activation thresholds, which is highly relevant in models of cancer, infection, autoimmune disease, and inflammation.
• Modulating immune responses in disease models: OX-90 is often applied in studies investigating how CD200 contributes to immune regulation in various contexts, notably:
  • Cancer immunology, to reverse tumor-induced immune suppression.
  • Autoimmune and inflammatory diseases, to study loss of immune tolerance or enhanced inflammation when CD200 is blocked.
• Immune cell depletion or functional modulation: While not a primary depleting antibody, OX-90 can modulate the immune function of cells expressing CD200—including thymocytes, B cells, subsets of T cells, neurons, and dendritic cells—in systemic or tissue-specific studies.
• Functional studies of CD200 signaling: In vivo administration is used to elucidate the physiological role of CD200 in regulating cytokine induction, T cell proliferation, suppression of mast cell degranulation, and the attenuation of immune activation.

Important technical details:

• OX-90 is a rat IgG2a monoclonal antibody specific to mouse CD200 (OX-2) and is typically provided in low or ultra-low endotoxin formulations for compatibility with sensitive in vivo experiments.
• It is appropriate for both acute and chronic dosing regimens, depending on the disease model and experimental question.

Most reported in vivo uses revolve around functional blockade rather than mere detection, utilizing the antibody’s capacity to disrupt normal CD200 signaling to uncover immune regulatory mechanisms and their relevance to disease.

OX-90 is a monoclonal antibody that specifically recognizes murine CD200 (OX-2), a membrane glycoprotein involved in immune regulation. In scientific literature and experimental practice, OX-90 is commonly used in combination with several other antibodies or protein markers depending on the aim of the study.

Commonly Co-Used Antibodies or Proteins with OX-90:

• CD45: A pan-leukocyte marker typically used in flow cytometry to identify all leukocytes.
• CD3, CD4, CD8: T-cell markers help in delineating T-cell subsets within lymphoid populations.
• CD11b, F4/80: Myeloid markers for identifying monocytes and macrophages.
• CD19 and CD20: B-cell specific markers when studying lymphocyte populations.
• CD90 (Thy-1.1/Thy-1): Especially relevant when distinguishing cell populations in rats and mice, as CD90 is another glycoprotein present on T cells and some neuronal lineages.
• CD86, CD80, MHC II: Frequently assessed in immune regulation and antigen presentation investigations.
• CD200R: The receptor for CD200, sometimes studied alongside CD200 to probe interaction and signaling pathways.

In immunophenotyping or immune modulation studies, OX-90 is often used to evaluate CD200 expression alongside lymphocyte or myeloid lineage markers, particularly in the context of immunoregulation, neuroinflammation, and graft-tolerance scenarios. For example, an experiment might combine OX-90 to detect CD200 with anti-CD45 to gate leukocytes, and anti-CD3/CD19 to parse T and B cells respectively.

CD90 (Thy-1) and OX-2 (CD200) in Murine Models:

• Both OX-7 (CD90) and OX-90 (CD200) antibodies are widely used in mouse and rat studies for lineage tracing or depletion experiments, and often appear together in immunophenotyping panels.

In summary: OX-90 is most frequently used with lineage markers such as CD45, CD3, CD4, CD8, CD11b, F4/80, CD19, and CD90 (OX-7), as well as functional markers like CD86, CD80, and MHC II. The specific combination depends on the experimental context but generally revolves around immune cell characterization and functional studies.

The clone OX-90 is primarily associated with the CD200 (OX2) antigen, which is recognized by a rat monoclonal antibody. This antibody is widely used in various research applications, including flow cytometry, immunohistochemistry, and ELISA. Key findings involving clone OX-90 from scientific literature focus on its role in detecting mouse CD200/OX2 and its implications in immunological studies.

Key Findings

1. CD200 Expression and Function: CD200 (OX2) is expressed by splenic B lymphocytes, follicular dendritic cells, splenic endothelium, and neurons. It plays a crucial role in the control of macrophage and granulocyte activation through its interaction with the CD200 receptor.

2. Immunological Studies: The CD200-CD200 receptor interaction is known to down-regulate the macrophage lineage, influencing immune responses. Studies using the OX-90 clone have contributed to understanding these interactions and their implications in immune regulation.

3. Flow Cytometry and Immunohistochemistry: Clone OX-90 is used in flow cytometry and immunohistochemistry to study cell populations expressing CD200 in mice. This facilitates research into the distribution and role of CD200 in different tissues.

4. Research Applications: The versatility of the OX-90 antibody allows it to be employed in various research settings, including basic immunology research and studies on neutrophil and macrophage interactions.

Conclusion

Citations involving clone OX-90 highlight its utility in studying CD200/OX2 and its role in modulating immune responses. The antibody's applications span multiple research techniques, making it a valuable tool in immunological research.

However, the search results do not provide comprehensive details on specific studies or findings directly attributed to clone OX-90 citations. For detailed insights, reviewing specific scientific articles that use this clone would be necessary.

Dosing regimens for clone OX-90 antibody in mouse models are typically determined by experimental goals and application, but published protocols primarily use concentrations for ex vivo assays rather than in vivo dosing, and standardized in vivo dosing information for OX-90 is scarce in current literature.

Key details from available sources:

• For ex vivo assays such as flow cytometry, ELISA, and immunohistochemistry, clone OX-90 is commonly used at concentrations of 10 μg/mL for tissue staining or according to lot-specific manufacturer recommendations.
• Most suppliers specify dilution ranges and refer users to controls such as mouse spleen tissue, but do not cite standardized in vivo dosing regimens such as those available for more widely used therapeutic or depleting antibody clones (e.g., 9H10 for anti-CTLA-4).
• No source explicitly details variation in in vivo OX-90 dosing across different mouse strains or disease models.

Experimental Variables:

• For other antibody clones, dosing regimens can vary considerably based on:
  • Mouse strain: Immunological baseline and pharmacokinetics may differ between C57BL/6, BALB/c, and humanized strains.
  • Sex: Some studies report sex-dependent responses in drug pharmacokinetics and toxicity.
  • Disease model: Tumor immunotherapy, inflammation, or other disease states may require different dosing schedules and amounts.

Limitations:

• No peer-reviewed sources or manufacturer protocols currently outline systematic in vivo OX-90 dosing regimens by mouse strain or application.
• Researchers wishing to use OX-90 in vivo should calibrate dosing empirically or contact suppliers for specific recommendations, potentially referencing related dosing strategies from similar monoclonal antibody studies.

In summary:
Clone OX-90 is mostly used at defined concentrations for ex vivo applications (e.g., 10 μg/mL for tissue staining), and there is no publicly available standardized dosing regimen for in vivo use, nor documentation of how regimens vary across mouse models. Researchers typically refer to analogous antibody dosing protocols and adjust by empirical optimization.